15 Jul 2013
Surgical intervention is not feasible in aggressive metastatic bronchial carcinoids (BCs), and current mTOR inhibitors have had mixed clinical success. Gagliano and colleagues assessed a novel PI3K/mTOR inhibitor, NVP-BEZ235, in everolimus-resistant human BCs. They found that NVP-BEZ235 is twice as effective as everolimus in BCs which are sensitive to mTOR inhibitors, but not effective in everolimus-resistant BC tissues. They go on to identify 3 markers, which may be clinically useful in identifying BCs which may respond to mTOR inhibitor treatment.
Read the full article in Gagliano et al (2013) Endocrine-Related Cancer 20; 463-475; DOI: 10.1530/ERC-13-0042.
New Awards Committee Chair
29 Jan 2025
Society for Endocrinology endorses landmark guidelines for childhood pituitary tumour care
29 Jan 2025
Announcing the Winners of the SfE Emerging Researcher Lectures 2025
23 Jan 2025
Congratulations to the awardees of our third round of 2024 grants
22 Jan 2025